128 related articles for article (PubMed ID: 1459314)
1. Intermediate and long-acting insulin preparations without protamine sulphate are complement activators in vitro.
Duchateau J; Schreyen H; Dorchy H
Diabete Metab; 1992; 18(4):272-6. PubMed ID: 1459314
[TBL] [Abstract][Full Text] [Related]
2. Heparin-protamine complexes and C-reactive protein induce activation of the classical complement pathway: studies in patients undergoing cardiac surgery and in vitro.
Bruins P; te Velthuis H; Eerenberg-Belmer AJ; Yazdanbakhsh AP; de Beaumont EM; Eijsman L; Trouwborst A; Hack CE
Thromb Haemost; 2000 Aug; 84(2):237-43. PubMed ID: 10959695
[TBL] [Abstract][Full Text] [Related]
3. Absorption kinetics and action profiles of intermediate acting human insulins.
Bilo HJ; Heine RJ; Sikkenk AC; van der Meer J; van der Veen EA
Diabetes Res; 1987 Jan; 4(1):39-43. PubMed ID: 3552366
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and miscibility of 4 highly purified porcine insulins: a study in vitro and in healthy volunteers.
Heine RJ; Van der Stap H; Salemink PJ; Kolkman-Roodbeen JC; Banken P; Gribnau TC; van der Veen EA
Diabetes Res; 1987 Jan; 4(1):45-50. PubMed ID: 3552367
[TBL] [Abstract][Full Text] [Related]
5. [A study of the absorption of NPH insulin administered into subcutaneous tissue: in vitro study of the mechanism of insulin release from NPH insulin crystal].
Yanagisawa K
Hokkaido Igaku Zasshi; 1992 Jan; 67(1):81-8. PubMed ID: 1559663
[TBL] [Abstract][Full Text] [Related]
6. Complement activation during cardiopulmonary bypass by heparin-protamine interaction.
Best N; Sinosich MJ; Teisner B; Grudzinskas JG; Fisher MM
Br J Anaesth; 1984 Apr; 56(4):339-43. PubMed ID: 6608952
[TBL] [Abstract][Full Text] [Related]
7. [Ultratard HM, a new human insulin. Advantages as compared to current preparations?].
Saner B; Fankhauser S
Schweiz Med Wochenschr; 1986 Jan; 116(4):116-9. PubMed ID: 3513303
[TBL] [Abstract][Full Text] [Related]
8. Evidence for complement activation by protamine-heparin interaction after cardiopulmonary bypass.
Cavarocchi NC; Schaff HV; Orszulak TA; Homburger HA; Schnell WA; Pluth JR
Surgery; 1985 Sep; 98(3):525-31. PubMed ID: 3875906
[TBL] [Abstract][Full Text] [Related]
9. Structural characterization of insulin NPH formulations.
Norrman M; Hubálek F; Schluckebier G
Eur J Pharm Sci; 2007 Apr; 30(5):414-23. PubMed ID: 17339105
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two ultralente insulin preparations with protamine zinc insulin in clinically normal cats.
Broussard JD; Peterson ME
Am J Vet Res; 1994 Jan; 55(1):127-31. PubMed ID: 8141485
[TBL] [Abstract][Full Text] [Related]
11. Anaphylaxis to subcutaneous neutral protamine Hagedorn insulin with simultaneous sensitization to protamine and insulin.
Blanco C; Castillo R; Quiralte J; Delgado J; García I; de Pablos P; Carrillo T
Allergy; 1996 Jun; 51(6):421-4. PubMed ID: 8837667
[TBL] [Abstract][Full Text] [Related]
12. Protamine sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity.
Barstad RM; Stephens RW; Hamers MJ; Sakariassen KS
Thromb Haemost; 2000 Feb; 83(2):334-7. PubMed ID: 10739395
[TBL] [Abstract][Full Text] [Related]
13. Normalization of complement activation and consumption in diabetic children and adolescents after switch-over from porcine to semisynthetic human insulin.
Dorchy H; Duchateau J; D'Hooge D
Diabete Metab; 1988; 14(4):415-21. PubMed ID: 3066649
[TBL] [Abstract][Full Text] [Related]
14. Binding of C-reactive protein to nucleated cells leads to complement activation without cytolysis.
Berman S; Gewurz H; Mold C
J Immunol; 1986 Feb; 136(4):1354-9. PubMed ID: 3944459
[TBL] [Abstract][Full Text] [Related]
15. Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro.
Weiler JM; Gleich GJ
J Immunol; 1988 Mar; 140(5):1605-10. PubMed ID: 3346544
[TBL] [Abstract][Full Text] [Related]
16. Properties of glycans that activate the human alternative complement pathway and interact with the human monocyte beta-glucan receptor.
Czop JK; Austen KF
J Immunol; 1985 Nov; 135(5):3388-93. PubMed ID: 4045195
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons.
Soulika AM; Khan MM; Hattori T; Bowen FW; Richardson BA; Hack CE; Sahu A; Edmunds LH; Lambris JD
Clin Immunol; 2000 Sep; 96(3):212-21. PubMed ID: 10964539
[TBL] [Abstract][Full Text] [Related]
18. Screening for subclinical complications in young type 1 diabetic patients: experience acquired in Brussels.
Dorchy H
Pediatr Endocrinol Rev; 2004 Jun; 1(4):380-403. PubMed ID: 16437030
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the pharmacokinetics of human protamine sodium insulin with human isophane insulin following subcutaneous injection in normal subjects.
Burke B; Andrews WJ; Hadden DR
Diabetes Res; 1987 Apr; 4(4):163-7. PubMed ID: 3304782
[TBL] [Abstract][Full Text] [Related]
20. The effect of insulin mixtures in type I diabetics: influence of the intermediate acting insulin on the action of short acting insulin.
Goicolea I; Quiroga A; Vazquez JA
Diabete Metab; 1987; 13(4):467-70. PubMed ID: 3315768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
